Mechanisms for depleting tumor immunity in AIDS

艾滋病中肿瘤免疫耗竭的机制

基本信息

  • 批准号:
    8063017
  • 负责人:
  • 金额:
    $ 49.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-06-01 至 2013-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Human V?2V?2 T cells respond to low molecular weight isoprenoid pyrophosphate antigens and exhibit cytotoxicity against a variety of human tumors. Cells expressing this T cell receptor are depleted early in HIV disease and their loss is associated with increased risk for malignant disease and opportunistic infections in AIDS. Recently, we reported (Alexander, et al., 2008) that the subset of ??T cells expressing cell surface CD56 is potently cytotoxic against squamous cell carcinoma cell lines and resists TNF? or Fas-mediated cellular apoptosis. CD56 is regulated by the Runx1 transcription factor and increases after stimulation by common ? chain cytokines, possibly reflecting STAT 5 activation that would free Runx1 for nuclear translocation. Cell surface CD56 on V?2V?2 was a costimulatory receptor, promoting phosphorylation of Akt-1 and apoptosis resistance. Based on these and additional data, we proposed a model for the control of ?? T cell levels: Expression of CD56 and the apoptosis resistance phenotype favored accumulation of antigen- experienced cells in the circulating population and higher expression of CD56 was associated with higher baseline V?2V?2 levels. In HIV disease, there is specific depletion of V?2V?2+ cells that is presumed to occur by indirect mechanisms because the cells do not express CD4 and are not susceptible to HIV infection in vitro. To date, the mechanism for depletion is not known. Our recent studies revealed phenotypic differences in those V?2V?2 cells remaining in HIV+ individuals (concentrating on donors with >300 CD4 T cells/mm3), including a significantly decreased capacity for expressing CD56 after cytokine stimulation. Without CD56 we predict lower Akt-1 phosphorylation and an apoptosis-sensitive phenotype. In the pre-apoptotic environment of HIV infection, sensitive cells would be depleted more rapidly. This is a plausible and testable model for the loss of V?2V?2 cells during HIV disease. Our proposal defines individual steps in the pathway for V?2V?2 cell activation and expression of the apoptosis-resistant phenotype and compares these mechanisms with cells from control and HIV+ donors. Control cells are manipulated to mimic the behavior of cells from HIV donors and HIV donor cells are altered to increase CD56 expression and apoptosis-resistance. Specific cytokines or alternate costimulatory molecules are substituted for CD56 and IL-2 to search for means to activate and potentially reconstitute V?2V?2 cells in HIV+ individuals. Recent studies implicated the Nef protein as an agonist for peroxisome proliferator activated receptor (PPAR) that would decrease Akt-1 activation and potentially decrease apoptosis-resistance in ???T cells. We will test Nef to determine whether this viral accessory protein has a role in the ??T cell depletion mechanism. PUBLIC HEALTH RELEVANCE: During HIV infection, T lymphocytes are depleted after direct virus infection, in the case of CD4+ cells, and by indirect means for other cells that do not express the virus receptor. Our studies focus on the CD4-negative ??T cells that are depleted early in HIV disease and their loss reduces natural immunity to cancer and infectious disease. The research investigates intracellular signaling pathways that control cell functions, to uncover defects associated with HIV infection. Knowledge of these defects and potentially understanding the viral proteins responsible for these defects, is proximal to designing new therapy approaches to recover ?? T cells in persons with HIV disease.
描述(申请人提供):人类V?2V?2T细胞对低分子量的类异戊二烯焦磷酸抗原有反应,并对多种人类肿瘤表现出细胞毒作用。表达这种T细胞受体的细胞在HIV疾病早期就被耗尽,它们的丢失与艾滋病中恶性疾病和机会性感染的风险增加有关。最近,我们(Alexander,et al.,2008)报道,表达细胞表面CD56的T细胞亚群对鳞状细胞癌细胞株具有很强的细胞毒作用,并能抵抗肿瘤坏死因子?或Fas介导的细胞凋亡。CD56受RUNX1转录因子调控,受普通?链状细胞因子,可能反映STAT5的激活,从而释放RUNX1进行核转位。V2V2细胞表面CD56是一种共刺激受体,促进Akt-1的磷酸化和抗凋亡作用。基于这些数据和补充数据,我们提出了一个控制??T细胞水平:CD56的表达和抗凋亡表型有利于抗原感受细胞在循环人群中的聚集,CD56的高表达与基础V 2V2水平的升高相关。在HIV疾病中,V、2V、2+细胞的特异性耗竭可能是通过间接机制发生的,因为这些细胞不表达CD4并且在体外对HIV感染不敏感。到目前为止,耗尽的机制尚不清楚。我们最近的研究揭示了HIV+个体(集中在拥有300个CD4T细胞/mm3的捐赠者)中残留的V?2V?2细胞的表型差异,包括细胞因子刺激后表达CD56的能力显著降低。如果没有CD56,我们预测Akt-1的磷酸化程度较低,并出现对凋亡敏感的表型。在艾滋病毒感染的前凋亡环境中,敏感细胞会更快地耗尽。这是一种可信的、可检验的在HIV疾病过程中V?2V?2细胞丢失的模型。我们的建议定义了V?2V?2细胞激活和抗凋亡表型表达途径中的各个步骤,并将这些机制与对照组和HIV+捐赠者的细胞进行了比较。对照细胞被操纵来模仿来自HIV捐赠者的细胞的行为,而HIV捐赠者细胞被改变以增加CD56的表达和抗凋亡能力。用特定的细胞因子或交替的共刺激分子来替代CD56和IL-2,以寻找激活和潜在地重建HIV+患者V?2V?2细胞的方法。最近的研究表明,Nef蛋白是过氧化物酶体增殖物激活受体(PPAR)的激动剂,可降低Akt-1的活性,并潜在地降低T细胞的抗凋亡能力。我们将测试Nef以确定这种病毒辅助蛋白是否在T细胞耗尽机制中发挥作用。公共卫生相关性:在艾滋病毒感染期间,T淋巴细胞在病毒直接感染后被耗尽,在CD4+细胞的情况下,并通过间接方式对不表达病毒受体的其他细胞。我们的研究集中在HIV疾病早期耗尽的CD4阴性T细胞,它们的丢失降低了对癌症和传染病的自然免疫力。这项研究调查了控制细胞功能的细胞内信号通路,以揭示与艾滋病毒感染相关的缺陷。了解这些缺陷并可能了解导致这些缺陷的病毒蛋白,是否接近设计新的治疗方法来恢复?HIV感染者体内的T细胞。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

C. David Pauza其他文献

C. David Pauza的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('C. David Pauza', 18)}}的其他基金

T-follicular helper cells in Env-immunized macaques
Env 免疫猕猴中的滤泡辅助 T 细胞
  • 批准号:
    8262539
  • 财政年份:
    2012
  • 资助金额:
    $ 49.83万
  • 项目类别:
FcRn-targeted mucosal HIV vaccine
FcRn 靶向粘膜 HIV 疫苗
  • 批准号:
    8513912
  • 财政年份:
    2012
  • 资助金额:
    $ 49.83万
  • 项目类别:
Synthetic Variable Domain Glycopeptides for Neutralizing Epitope Characterization
用于中和表位表征的合成可变结构域糖肽
  • 批准号:
    8505372
  • 财政年份:
    2012
  • 资助金额:
    $ 49.83万
  • 项目类别:
FcRn-targeted mucosal HIV vaccine
FcRn 靶向粘膜 HIV 疫苗
  • 批准号:
    8685882
  • 财政年份:
    2012
  • 资助金额:
    $ 49.83万
  • 项目类别:
FcRn-targeted mucosal HIV vaccine
FcRn 靶向粘膜 HIV 疫苗
  • 批准号:
    8409840
  • 财政年份:
    2012
  • 资助金额:
    $ 49.83万
  • 项目类别:
T-follicular helper cells in Env-immunized macaques
Env 免疫猕猴中的滤泡辅助 T 细胞
  • 批准号:
    8515924
  • 财政年份:
    2012
  • 资助金额:
    $ 49.83万
  • 项目类别:
Mechanisms for depleting tumor immunity in AIDS
艾滋病中肿瘤免疫耗竭的机制
  • 批准号:
    7759088
  • 财政年份:
    2009
  • 资助金额:
    $ 49.83万
  • 项目类别:
Mechanisms for depleting tumor immunity in AIDS
艾滋病中肿瘤免疫耗竭的机制
  • 批准号:
    8138115
  • 财政年份:
    2009
  • 资助金额:
    $ 49.83万
  • 项目类别:
Mechanisms for depleting tumor immunity in AIDS
艾滋病中肿瘤免疫耗竭的机制
  • 批准号:
    8254371
  • 财政年份:
    2009
  • 资助金额:
    $ 49.83万
  • 项目类别:
Racial Disparity in gamma/delta T cells
γ/δ T 细胞的种族差异
  • 批准号:
    7492579
  • 财政年份:
    2008
  • 资助金额:
    $ 49.83万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 49.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 49.83万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 49.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 49.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 49.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 49.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 49.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 49.83万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 49.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 49.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了